Efficacy of pembrolizumab combined with anlotinib in 3 patients with advanced non-small cell lung cancer

Detalhes bibliográficos
Autor(a) principal: ZHU,Haoshuai
Data de Publicação: 2022
Outros Autores: ZENG,Bo, ZOU,Jianyong, SU,Chunhua
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Food Science and Technology (Campinas)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-20612022000100632
Resumo: Abstract Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer and accounts for about 85% of all lung cancers. Pembrolizumab, a PD-1 inhibitor, is approved to treat patients with advanced NSCLC. Anlotinib, a multi-target tyrosine kinase inhibitor, is approved in China for treating patients with advanced NSCLC with progression or recurrence after ≥ 2 lines of systemic chemotherapy. Whether pembrolizumab combined with anlotinib has synergistic effects on treating advanced NSCLC patients remains unclear. Here we reported that three cases of patients with advanced NSCLC had a good response and a long time of PR to pembrolizumab combined with anlotinib treatment, indicating that combined administration of pembrolizumab and anlotinib can be optional management for advanced NSCLC.
id SBCTA-1_1b3f754fde49bc43bc9b21b134f5e6f8
oai_identifier_str oai:scielo:S0101-20612022000100632
network_acronym_str SBCTA-1
network_name_str Food Science and Technology (Campinas)
repository_id_str
spelling Efficacy of pembrolizumab combined with anlotinib in 3 patients with advanced non-small cell lung cancerNon-small-cell lung carcinoma (NSCLC)pembrolizumabanlotinibAbstract Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer and accounts for about 85% of all lung cancers. Pembrolizumab, a PD-1 inhibitor, is approved to treat patients with advanced NSCLC. Anlotinib, a multi-target tyrosine kinase inhibitor, is approved in China for treating patients with advanced NSCLC with progression or recurrence after ≥ 2 lines of systemic chemotherapy. Whether pembrolizumab combined with anlotinib has synergistic effects on treating advanced NSCLC patients remains unclear. Here we reported that three cases of patients with advanced NSCLC had a good response and a long time of PR to pembrolizumab combined with anlotinib treatment, indicating that combined administration of pembrolizumab and anlotinib can be optional management for advanced NSCLC.Sociedade Brasileira de Ciência e Tecnologia de Alimentos2022-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-20612022000100632Food Science and Technology v.42 2022reponame:Food Science and Technology (Campinas)instname:Sociedade Brasileira de Ciência e Tecnologia de Alimentos (SBCTA)instacron:SBCTA10.1590/fst.33621info:eu-repo/semantics/openAccessZHU,HaoshuaiZENG,BoZOU,JianyongSU,Chunhuaeng2022-02-22T00:00:00Zoai:scielo:S0101-20612022000100632Revistahttp://www.scielo.br/ctaONGhttps://old.scielo.br/oai/scielo-oai.php||revista@sbcta.org.br1678-457X0101-2061opendoar:2022-02-22T00:00Food Science and Technology (Campinas) - Sociedade Brasileira de Ciência e Tecnologia de Alimentos (SBCTA)false
dc.title.none.fl_str_mv Efficacy of pembrolizumab combined with anlotinib in 3 patients with advanced non-small cell lung cancer
title Efficacy of pembrolizumab combined with anlotinib in 3 patients with advanced non-small cell lung cancer
spellingShingle Efficacy of pembrolizumab combined with anlotinib in 3 patients with advanced non-small cell lung cancer
ZHU,Haoshuai
Non-small-cell lung carcinoma (NSCLC)
pembrolizumab
anlotinib
title_short Efficacy of pembrolizumab combined with anlotinib in 3 patients with advanced non-small cell lung cancer
title_full Efficacy of pembrolizumab combined with anlotinib in 3 patients with advanced non-small cell lung cancer
title_fullStr Efficacy of pembrolizumab combined with anlotinib in 3 patients with advanced non-small cell lung cancer
title_full_unstemmed Efficacy of pembrolizumab combined with anlotinib in 3 patients with advanced non-small cell lung cancer
title_sort Efficacy of pembrolizumab combined with anlotinib in 3 patients with advanced non-small cell lung cancer
author ZHU,Haoshuai
author_facet ZHU,Haoshuai
ZENG,Bo
ZOU,Jianyong
SU,Chunhua
author_role author
author2 ZENG,Bo
ZOU,Jianyong
SU,Chunhua
author2_role author
author
author
dc.contributor.author.fl_str_mv ZHU,Haoshuai
ZENG,Bo
ZOU,Jianyong
SU,Chunhua
dc.subject.por.fl_str_mv Non-small-cell lung carcinoma (NSCLC)
pembrolizumab
anlotinib
topic Non-small-cell lung carcinoma (NSCLC)
pembrolizumab
anlotinib
description Abstract Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer and accounts for about 85% of all lung cancers. Pembrolizumab, a PD-1 inhibitor, is approved to treat patients with advanced NSCLC. Anlotinib, a multi-target tyrosine kinase inhibitor, is approved in China for treating patients with advanced NSCLC with progression or recurrence after ≥ 2 lines of systemic chemotherapy. Whether pembrolizumab combined with anlotinib has synergistic effects on treating advanced NSCLC patients remains unclear. Here we reported that three cases of patients with advanced NSCLC had a good response and a long time of PR to pembrolizumab combined with anlotinib treatment, indicating that combined administration of pembrolizumab and anlotinib can be optional management for advanced NSCLC.
publishDate 2022
dc.date.none.fl_str_mv 2022-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-20612022000100632
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-20612022000100632
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/fst.33621
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Ciência e Tecnologia de Alimentos
publisher.none.fl_str_mv Sociedade Brasileira de Ciência e Tecnologia de Alimentos
dc.source.none.fl_str_mv Food Science and Technology v.42 2022
reponame:Food Science and Technology (Campinas)
instname:Sociedade Brasileira de Ciência e Tecnologia de Alimentos (SBCTA)
instacron:SBCTA
instname_str Sociedade Brasileira de Ciência e Tecnologia de Alimentos (SBCTA)
instacron_str SBCTA
institution SBCTA
reponame_str Food Science and Technology (Campinas)
collection Food Science and Technology (Campinas)
repository.name.fl_str_mv Food Science and Technology (Campinas) - Sociedade Brasileira de Ciência e Tecnologia de Alimentos (SBCTA)
repository.mail.fl_str_mv ||revista@sbcta.org.br
_version_ 1752126332375924736

Registros relacionados